Aclaris Therapeutics (ACRS) Piper Sandler 36th Annual Healthcare Conference summary

Company overview and recent developments

• Focuses on small and large molecule therapeutics for immunoinflammatory diseases, with two clinical-stage assets and a near-clinic bispecific asset acquired from Biosion.

• Recent in-licensing deal brought TSLP monoclonal antibody and bispecific, both deep into phase 2, and added senior leadership from Biosion.

• Financing secured to support development through 2028.

Details of the Biosion deal

• The deal was highly competitive, secured through a mix of equity and relationship-building with Biosion's leadership.

• Data maturity and exclusivity timing allowed for favorable deal terms.

• Internal validation and competitive analysis confirmed the assets' differentiation, especially versus Tezspire.

Data validation and clinical strategy

• Repeated Biosion's preclinical work in-house and at WuXi AppTec to ensure data reliability.

• Upcoming phase 2 respiratory data in severe asthma and CRS with nasal polyps expected in the first half of next year.

• Data sharing rights with partners enable rapid advancement if results are positive.